| Literature DB >> 36058412 |
Yong Yin1, Jilei Lin1, Shuhua Yuan1, Shilu Tong2, Erzhen Chen3, Junhua Zheng4, Wei Wang5.
Abstract
Entities:
Year: 2022 PMID: 36058412 PMCID: PMC9433329 DOI: 10.1016/j.jinf.2022.08.034
Source DB: PubMed Journal: J Infect ISSN: 0163-4453 Impact factor: 38.637
The characteristics of study participants.
| Total | From illness onset to being admitted to hospitals | ||
|---|---|---|---|
| Early isolation (≤3 days) | Late isolation (>3 days) | ||
| Sample size | 199,590 | 152,746 | 46,844 |
| Sex (male,%) | 118,211 (59.23%) | 91,007 (59.58%) | 27,204 (58.07%) |
| Mean age (years old, | 41.44 ± 15.38 | 41.08 ± 15.29 | 42.61 ± 15.62 |
| Age group (n,%) | |||
| <18 y | 10,209 (5.11%) | 7439 (4.87%) | 2770 (5.91%) |
| 18∼59y | 165,569 (82.95%) | 127,456 (83.44%) | 38,113 (81.36%) |
| ≥60 y | 23,812 (11.93%) | 17,851 (11.69%) | 5961 (12.73%) |
| Underlying diseases (Yes,%) | 13,436 (6.73%) | 9735 (6.37%) | 3701 (7.90%) |
| Types of vaccine (n,%) | |||
| Unvaccinated | 43,998 (22.04%) | 34,743 (22.75%) | 9255 (19.76%) |
| Inactivated vaccine | 149,530 (74.92%) | 113,199 (74.11%) | 36,331 (77.56%) |
| Adenovirus vector vaccine | 3960 (1.98%) | 3108 (2.04%) | 853 (1.82%) |
| Protein subunit vaccine | 2102 (1.05%) | 1696 (1.11%) | 406 (0.87%) |
| Vaccination status (n,%) | |||
| Unvaccinated | 43,998 (22.04%) | 34,743 (22.75%) | 9255 (19.76%) |
| Partial | 5087 (2.55%) | 3895 (2.55%) | 1192 (2.55%) |
| Full (without booster) | 64,406 (32.27%) | 48,653 (31.85%) | 15,753 (33.63%) |
| Booster | 86,099 (43.14%) | 65,455 (42.85%) | 20,644 (44.07%) |
| DVS (days, | 7.17 ± 3.42 | 6.51 ± 3.3 | 9.34 ± 2.87 |
| DVS ≥7 days (n,%) | 108,547 (54.38%) | 66,973 (43.85%) | 41,574 (88.75%) |
| DVS ≥10 days (n,%) | 43,746 (21.92%) | 26,190 (17.15%) | 17,556 (37.48%) |
| DVS ≥14 days (n,%) | 9009 (4.51%) | 5159 (3.38%) | 3850 (8.22%) |
| Days from illness onset to being admitted to hospitals (days, | 2.27 ± 1.84 | 1.42 ± 0.97 | 5.07 ± 1.06 |
| Early isolation (n,%) | 152,746 (76.53%) | 152,746 (100%) | 0 |
Duration of viral shedding: the time from illness onset to the negative viral load; m±sd: mean± standard deviation.
The association between TLDA and DVS.
| Outcomes | Crude OR (95%CI) | P | Adjusted OR (95%CI) | P |
|---|---|---|---|---|
| TLDA (Continuous) | ||||
| DVS (Continuous) | 2.25 (2.23, 2.27) | <0.001 | 2.25 (2.23, 2.26) | <0.001 |
| DVS ≥7 days | 1.82 (1.81, 1.83) | <0.001 | 1.83 (1.81, 1.84) | <0.001 |
| DVS ≥10 days | 1.38 (1.37, 1.39) | <0.001 | 1.38 (1.38, 1.39) | <0.001 |
| DVS ≥14 days | 1.31 (1.30, 1.32) | <0.001 | 1.31 (1.30, 1.33) | <0.001 |
| TLDA (Categorical, Reference= early isolation) | ||||
| DVS (Continuous) | 16.91 (16.36, 17.48) | <0.001 | 16.79 (16.24, 17.35) | <0.001 |
| DVS ≥7 days | 10.10 (9.80, 10.42) | <0.001 | 10.18 (9.88, 10.50) | <0.001 |
| DVS ≥10 days | 2.90 (2.83, 2.96) | <0.001 | 2.93 (2.87, 3.00) | <0.001 |
| DVS ≥14 days | 2.56 (2.45, 2.67) | <0.001 | 2.58 (2.47, 2.69) | <0.001 |
Adjusted: Models were adjusted by underlying diseases (yes or no), age (<18, 18∼59, and ≥60 years old), vaccination status (unvaccinated, partial, full and booster vaccination), and types of vaccine (unvaccinated, inactivated vaccine, adenovirus vector vaccine and protein subunit vaccine).
TLDA: The time lag from diagnosis to isolation (days); DVS: the duration of viral shedding; OR: odds ratio; CIs: confidence intervals; early isolation: the time from diagnosis to isolation ≤3 days.